Omeros Corp (OMER) shareholders
Close on Nov 17, 2026Market cap $1.01BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 5,961,792 | 8.20% | 13G (passive) amendment | Jun 30, 2026 |
| / Gregory A. Demopulos, M.D | 5,704,061 | 8.80% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of OMER | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,044,633 | 8.35% | $57.48M | +735,007 | 0.00% |
| Ingalls & Snyder LLC | 3,659,523 | 5.06% | $34.80M | +100,100 | 0.95% |
| UBS Group AG | 3,148,384 | 4.35% | $29.94M | +807,653 | 0.00% |
| Vanguard Capital Management LLC | 3,072,050 | 4.24% | $29.22M | +88,791 | 0.00% |
| State Street Corp | 2,319,906 | 3.20% | $22.06M | +400,331 | 0.00% |
| Geode Capital Management, LLC | 1,914,460 | 2.64% | $18.21M | +162,137 | 0.00% |
| Stifel Financial Corp | 1,836,925 | 2.54% | $17.47M | +5,340 | 0.01% |
| Vanguard Portfolio Management LLC | 962,828 | 1.33% | $9.16M | +244,153 | 0.00% |
| Invesco Ltd. | 751,771 | 1.04% | $7.15M | +571,142 | 0.00% |
| Northern Trust Corp | 727,348 | 1.00% | $6.92M | +163,481 | 0.00% |
| Rock Springs Capital Management LP | 718,499 | 0.99% | $6.83M | New | 0.33% |
| Corient Private Wealth LLC | 659,730 | 0.91% | $6.27M | −141,681 | 0.01% |
| Rubric Capital Management LP | 656,874 | 0.91% | $6.25M | New | 0.06% |
| Charles Schwab Investment Management Inc | 604,633 | 0.84% | $5.75M | +22,121 | 0.00% |
| Bank Of Montreal /Can/ | 568,424 | 0.79% | $5.41M | −2 | 0.00% |
| Vanguard Fiduciary Trust Co | 491,173 | 0.68% | $4.67M | −1,172 | 0.00% |
| Federated Hermes, Inc. | 478,290 | 0.66% | $4.55M | New | 0.01% |
| Clutterbuck Capital Management LLC | 450,000 | 0.62% | $4.28M | +150,000 | 2.43% |
| Two Sigma Investments, LP | 402,662 | 0.56% | $3.83M | +116,188 | 0.00% |
| Morgan Stanley | 394,459 | 0.54% | $3.75M | +76,567 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 172 | 36M | 49.9% | 36 / 68 | 42 / 25 | 7M | 2M |
| Q1 2026 | 162 | 31M | 42.6% | 37 / 62 | 41 / 22 | 7M | 5M |
| Q4 2025 | 151 | 34M | 46.9% | 33 / 61 | 35 / 13 | 9M | 8M |
| Q3 2025 | 133 | 33M | 46.0% | 15 / 57 | 31 / 9 | 6M | 2M |
| Q2 2025 | 127 | 30M | 40.9% | 16 / 44 | 36 / 25 | 5M | 3M |
| Q1 2025 | 137 | 28M | 38.1% | 22 / 35 | 50 / 12 | 3M | 2M |
| Q4 2024 | 128 | 27M | 36.7% | 31 / 49 | 27 / 11 | 3M | 1M |
| Q3 2024 | 108 | 25M | 34.6% | 16 / 27 | 34 / 8 | 5M | 1M |
| Q2 2024 | 104 | 25M | 34.5% | 17 / 24 | 32 / 12 | 1M | 2M |
| Q1 2024 | 99 | 26M | 35.8% | 14 / 28 | 33 / 12 | 2M | 1M |
| Q4 2023 | 97 | 25M | 34.9% | 12 / 27 | 32 / 14 | 1M | 3M |
| Q3 2023 | 100 | 27M | 37.2% | 10 / 33 | 24 / 13 | 3M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
135 funds held OMER in Q2 2026, 74% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of OMER | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,172,336 | 3.00% | $20.66M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,877,113 | 2.59% | $17.85M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 831,218 | 1.15% | $7.90M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 788,562 | 1.09% | $9.34M | 0.03% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 640,960 | 0.89% | $6.10M | 1.42% | Jun 30, 2026 |
| Invesco Biotechnology & Genome ETF | 601,237 | 0.83% | $7.12M | 2.52% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 417,582 | 0.58% | $3.97M | 0.03% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 366,516 | 0.51% | $4.05M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 352,679 | 0.49% | $3.89M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 343,807 | 0.47% | $3.80M | 0.02% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 252,978 | 0.35% | $2.41M | 0.02% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 240,842 | 0.33% | $2.29M | 0.15% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Growth Fund | 219,522 | 0.30% | $2.60M | 0.31% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 213,047 | 0.29% | $2.35M | 0.01% | May 31, 2026 |
| Vanguard U.S. Momentum Factor ETF | 191,200 | 0.26% | $2.11M | 0.11% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Gregory A. Demopulos MD | Chairman, CEO & President, Director | 2,250,931 | 3.11% | Oct 30, 2026 |
| David J. Borges | VP, Finance & CAO | 0 | – | Sep 24, 2026 |
| Peter B. Cancelmo | VP, General Counsel | 25,200 | 0.03% | Sep 1, 2026 |
| Arnold C. Hanish | Director | 14,900 | 0.02% | Aug 28, 2026 |
| Thomas J. Cable | Director | 50,067 | 0.07% | Aug 21, 2026 |
| Joseph L. Schocken | Director | 528,082 | 0.73% | Aug 18, 2026 |
| Peter A. Demopulos MD | Director | 372,898 | 0.52% | Jun 22, 2026 |
| Leroy E. MD Hood PhD | Director | 74,390 | 0.10% | Jun 22, 2026 |
| Rajiv Shah | Director | – | – | Jun 22, 2026 |
| Thomas F. Bumol | Director | 10,000 | 0.01% | Jun 22, 2026 |
| Diana T. Perkinson | Director | – | – | Jun 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David J. Borges VP, Finance & CAO | Sep 23, 2026 | Sale(10b5-1 plan) | −10,000 | $20.95 | $209.50K | 0 |
| David J. Borges VP, Finance & CAO | Sep 23, 2026 | Option exercise | +10,000 | $15.58 | $155.80K | 10,000 |
| David J. Borges VP, Finance & CAO | Sep 22, 2026 | Option exercise | +5,000 | $2.94 | $14.70K | 10,000 |
| David J. Borges VP, Finance & CAO | Sep 22, 2026 | Option exercise | +5,000 | $3.93 | $19.65K | 5,000 |
| David J. Borges VP, Finance & CAO | Sep 22, 2026 | Sale(10b5-1 plan) | −10,000 | $20.95 | $209.50K | 0 |
| Peter B. Cancelmo VP, General Counsel | Aug 31, 2026 | Option exercise | +25,000 | $2.94 | $73.50K | 25,200 |
| Peter B. Cancelmo VP, General Counsel | Aug 31, 2026 | Sale | −25,000 | $18.54 | $463.50K | 200 |
| Peter B. Cancelmo VP, General Counsel | Aug 28, 2026 | Sale | −25,000 | $18.65 | $466.25K | 200 |
| Peter B. Cancelmo VP, General Counsel | Aug 28, 2026 | Option exercise | +25,000 | $2.94 | $73.50K | 25,200 |
| Arnold C. Hanish Director | Aug 27, 2026 | Option exercise | +2,500 | $15.81 | $39.53K | 2,500 |
| Arnold C. Hanish Director | Aug 27, 2026 | Sale | −5,000 | $18.88 | $94.40K | 5,000 |
| Arnold C. Hanish Director | Aug 27, 2026 | Option exercise | +7,500 | $14.66 | $109.95K | 10,000 |
| Arnold C. Hanish Director | Aug 27, 2026 | Sale | −5,000 | $19.02 | $95.10K | 0 |
| Arnold C. Hanish Director | Aug 26, 2026 | Option exercise | +5,000 | $15.81 | $79.05K | 5,000 |
| Arnold C. Hanish Director | Aug 26, 2026 | Sale | −5,000 | $18.53 | $92.65K | 0 |
| David J. Borges VP, Finance & CAO | Aug 24, 2026 | Option exercise | +906 | $2.94 | $2.66K | 906 |
| David J. Borges VP, Finance & CAO | Aug 24, 2026 | Sale(10b5-1 plan) | −906 | $19.10 | $17.30K | 0 |
| David J. Borges VP, Finance & CAO | Aug 21, 2026 | Option exercise | +4,094 | $2.94 | $12.04K | 10,000 |
| David J. Borges VP, Finance & CAO | Aug 21, 2026 | Sale(10b5-1 plan) | −10,000 | $18.95 | $189.50K | 0 |
| David J. Borges VP, Finance & CAO | Aug 21, 2026 | Option exercise | +5,906 | $3.93 | $23.21K | 5,906 |
| Thomas J. Cable Director | Aug 20, 2026 | Option exercise | +7,500 | $3.93 | $29.48K | 50,067 |
| Thomas J. Cable Director | Aug 20, 2026 | Sale | −15,000 | $18.45 | $276.75K | 35,067 |
| Thomas J. Cable Director | Aug 20, 2026 | Option exercise | +7,500 | $2.00 | $15.00K | 42,567 |
| David J. Borges VP, Finance & CAO | Aug 13, 2026 | Option exercise | +5,000 | $3.93 | $19.65K | 5,000 |
| David J. Borges VP, Finance & CAO | Aug 13, 2026 | Sale(10b5-1 plan) | −5,000 | $16.95 | $84.75K | 0 |
| Thomas J. Cable Director | May 22, 2026 | Option exercise | +7,500 | $10.84 | $81.30K | 42,567 |
| Thomas J. Cable Director | May 22, 2026 | Sale(10b5-1 plan) | −7,500 | $11.61 | $87.08K | 35,067 |
| Gregory A. Demopulos MD Chairman, CEO & President, Director | Feb 18, 2026 | Option exercise | +400,000 | $10.27 | $4.11M | 1,826,986 |
| Gregory A. Demopulos MD Chairman, CEO & President, Director | Feb 18, 2026 | Tax withholding | −357,678 | $11.93 | $4.27M | 1,469,308 |
| David J. Borges VP, Finance & CAO | Jan 13, 2026 | Sale | −30,000 | $12.31 | $369.30K | 0 |
| David J. Borges VP, Finance & CAO | Jan 13, 2026 | Option exercise | +30,000 | $3.06 | $91.80K | 30,000 |
| David J. Borges VP, Finance & CAO | Jan 12, 2026 | Sale | −30,000 | $12.72 | $381.60K | 0 |
| Gregory A. Demopulos MD Chairman, CEO & President, Director | Oct 13, 2025 | Gift | −600,000 | – | – | 1,426,986 |
| Gregory A. Demopulos MD Chairman, CEO & President, Director | Oct 13, 2025 | Gift | +300,000 | – | – | 300,000 |
| Gregory A. Demopulos MD Chairman, CEO & President, Director | Oct 13, 2025 | Gift | +300,000 | – | – | 300,000 |
| Gregory A. Demopulos MD Chairman, CEO & President | Nov 17, 2023 | Buy | +15,000 | $1.68 | $25.20K | 123,945 |
| Peter A. Demopulos MD Director | Nov 15, 2023 | Buy | +10,000 | $1.53 | $15.30K | 208,516 |
| Gregory A. Demopulos MD Chairman, CEO & President | Nov 14, 2023 | Award | +25,000 | $1.44 | $36.00K | 108,945 |
| Gregory A. Demopulos MD Chairman, CEO & President | Nov 13, 2023 | Award | +37,500 | $1.29 | $48.38K | 83,945 |
| Thomas F. Bumol Director | Sep 12, 2023 | Award | +10,000 | $3.31 | $33.10K | 10,000 |
| Thomas J. Cable Director | May 22, 2023 | Option exercise | +5,000 | $5.30 | $26.50K | 40,067 |
| Thomas J. Cable Director | May 22, 2023 | Sale | −5,000 | $6.53 | $32.65K | 35,067 |
| Arnold C. Hanish Director | May 22, 2023 | Sale | −5,000 | $6.46 | $32.30K | 0 |
| Arnold C. Hanish Director | May 22, 2023 | Option exercise | +5,000 | $5.30 | $26.50K | 5,000 |
| Arnold C. Hanish Director | Sep 8, 2021 | Option exercise | +10,000 | $9.44 | $94.40K | 10,000 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | Jun 17, 2021 | Option exercise | +36,857 | $4.10 | $151.11K | 2,063,843 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | Jun 17, 2021 | Sale(10b5-1 plan) | −36,857 | $14.90 | $549.17K | 2,026,986 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | Jun 15, 2021 | Sale(10b5-1 plan) | −36,856 | $15.02 | $553.58K | 2,026,986 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | Jun 15, 2021 | Option exercise | +36,856 | $4.10 | $151.11K | 2,063,842 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | May 20, 2021 | Sale(10b5-1 plan) | −36,856 | $14.96 | $551.37K | 2,026,986 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | May 20, 2021 | Option exercise | +36,856 | $4.10 | $151.11K | 2,063,842 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | May 19, 2021 | Option exercise | +36,857 | $4.10 | $151.11K | 2,063,843 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | May 19, 2021 | Sale(10b5-1 plan) | −36,857 | $17.07 | $629.15K | 2,026,986 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | Apr 8, 2021 | Sale(10b5-1 plan) | −35,206 | $17.76 | $625.26K | 2,026,986 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | Apr 8, 2021 | Option exercise | +35,206 | $4.10 | $144.34K | 2,062,192 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | Apr 7, 2021 | Sale(10b5-1 plan) | −37,407 | $17.91 | $669.96K | 2,026,986 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | Apr 7, 2021 | Option exercise | +37,407 | $4.10 | $153.37K | 2,064,393 |
| Michael A. Jacobsen VP FINANCE AND CAO | Feb 22, 2021 | Option exercise | +8,100 | $10.27 | $83.19K | 22,100 |
| Michael A. Jacobsen VP FINANCE AND CAO | Feb 22, 2021 | Sale(10b5-1 plan) | −8,100 | $23.28 | $188.57K | 14,000 |
| Peter A. Demopulos MD Director | Feb 22, 2021 | Option exercise | +5,000 | $5.30 | $26.50K | 193,516 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Omeros's stock actually held short. Settlement fails (shares not delivered on time) peaked at 49,710 shares on Sep 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| David J. Borges Officer | Sep 23, 2026 | 14,927 | $314.21K | Sep 23, 2026 | Exercise of Stock Options |
| David J. Borges Officer | Sep 22, 2026 | 10,000 | $184.90K | Sep 22, 2026 | Exercise of Stock Options |
| Peter B. Cancelmo Officer | Aug 31, 2026 | 25,000 | $463.54K | Aug 31, 2026 | Exercise of Options Under a Registered Plan |
| Peter B. Cancelmo Officer | Aug 28, 2026 | 25,000 | $466.13K | Aug 28, 2026 | Exercise of Options Under a Registered Plan |
| Arnold C. Hanish Director | Aug 27, 2026 | 10,000 | $189.46K | Aug 27, 2026 | Exercise of Options Under a Registered Plan |
| Arnold C. Hanish Director | Aug 26, 2026 | 5,000 | $94.13K | Aug 26, 2026 | Exercise of Options Under a Registered Plan |
| David J. Borges Officer | Aug 21, 2026 | 10,906 | $203.18K | Aug 21, 2026 | Exercise of Stock Options |
| Thomas J. Cable Director | Aug 20, 2026 | 15,000 | $276.77K | Aug 20, 2026 | Exercise of Options Under a Registered Plan |
| David J. Borges Officer | Aug 13, 2026 | 5,000 | $68.55K | Aug 13, 2026 | Exercise of Stock Options |
| Thomas J. Cable Director | May 22, 2026 | 7,500 | $89.70K | May 22, 2026 | Exercise of Stock Options |
| David J. Borges Officer | Jan 13, 2026 | 30,000 | $369.32K | Jan 13, 2026 | Exercise of options under a registered plan |
| David J. Borges Officer | Jan 12, 2026 | 30,000 | $381.60K | Jan 12, 2026 | Open Market Purchase |
| Kurt Zumwalt Officer | Sep 20, 2023 | 7,500 | $22.67K | Sep 20, 2023 | Exercise of options under a registered plan |
| Thomas J. Cable Director | May 22, 2023 | 5,000 | $32.67K | May 22, 2023 | Exercise of options under a registered plan |
| Arnold C. Hanish Director | May 22, 2023 | 5,000 | $32.29K | May 22, 2023 | Exercise of options under a registered plan |
See a number that looks wrong?